Implications of the 2026 Dyslipidemia Guideline for Primary Prevention Statin Therapy
This cross-sectional study explores the 2026 guideline on dyslipidemia management, examining the population health impact on US adults recommended primary prevention statin therapy due to atherosclerotic cardiovascular disease risk.
Original Source
Read the full article at Jamanetwork →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.